ID: ALA364969

Max Phase: Preclinical

Molecular Formula: C15H14O2

Molecular Weight: 226.28

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(/C=C\c2ccccc2)cc1O

Standard InChI:  InChI=1S/C15H14O2/c1-17-15-10-9-13(11-14(15)16)8-7-12-5-3-2-4-6-12/h2-11,16H,1H3/b8-7-

Standard InChI Key:  QVPJESIABXRENB-FPLPWBNLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 226.28

Molecular Weight (Monoisotopic): 226.0994

AlogP: 3.57

#Rotatable Bonds: 3

Polar Surface Area: 29.46

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.84

CX Basic pKa:

CX LogP: 3.85

CX LogD: 3.85

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.81

Np Likeness Score: 0.52

References

1. Ducki S, Mackenzie G, Lawrence NJ, Snyder JP..  (2005)  Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.,  48  (2): [PMID:15658859] [10.1021/jm049444m]

2. Beale TM, Myers RM, Shearman JW, Charnock-Jones DS, Brenton JD, Gergely FV, Ley SV.  (2010)  Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4,  1  (3): [10.1039/C0MD00095G]

Source

Source(1):

• Scientific Literature